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SUMMARY ∑ Hypoglycemia may occur as a component of type 1 multiple endocrine neoplasia
syndrome. Insulinomas are rare tumors that often present a diagnostic dilemma for the clinician.
The presence of inappropriately high plasma insulin and C-peptide concentrations at the time of
symptomatic fasting hypoglycemia confirms the diagnosis of insulinoma. A. B., a 21-year-old girl,
presented for evaluation of recurrent episodes of hyperhidrosis, confusion, and weakness with tremor,
which was suggestive of hypoglycemia. Her body mass increased by 90 kg, with persistent symptoms
of hypoglycemia. Because of her extremely excess sive body weight of 158 kg, the only diagnostic
method available was upper abdomen ultrasonography, which revealed a tumor mass of 26 mm in
size, located at the tail of the pancreas. Hemipancreatectomy and splenectomy were performed in
one act. After the surgery, clinical symptoms disappeared but the patient developed diabetes, postop-
eratively, which required introduction of insulin therapy. Her body weight gradually normalized, she
lost 54 kg, and postoperative magnetic resonance and computed tomography controls produced nor-
mal findings.
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Introduction
Multiple endocrine neoplasia (MEN) syndrome de-
notes a rare, heritable disorder with predisposition to tu-
mors of the parathyroid glands, anterior pituitary, and
pancreatic islet cells (‘3 Ps’)1. Adenomas of the adrenal and
thyroid gland can also occur. The prevalence of multiple
endocrine neoplasia type 1 (MEN 1) is around 2 per
100,0002,3. A genetic linkage analysis has implicated a
region on the long arm of chromosome 11 (11q13) as the
site of the ‘MEN 1 gene’, but the mechanism by which
the genetic defect in MEN 1 leads to tumor formation has
not yet been clarified. The actual outgrowth of a tumor
is thought to require subsequent somatic inactivation,
often by gross deletion, of the normal copy of the gene in
one cell, and such cell would then be devoid of the MEN
1 gene’s normal tumor suppressor function and could gain
a selective advantage over its neighbors, resulting in clonal
proliferation4-9. Hyperparathyroidism is the most com-
mon manifestation of MEN 1, displaying almost 100%
penetrance by age 40-50.
Anterior pituitary disease, i.e. clinically apparent pi-
tuitary tumors, develop in 15% ∑ 20% of patients with
MEN 1 when sought by computed tomography (CT) or
magnetic resonance imaging (MRI), but the pathologic
prevalence of pituitary tumors may be over 60%10. The
most common type of pituitary tumor in MEN 1 is pro-
lactinoma. The prevalence of prolactinoma is more than
50% in some branches of the kindred, and accounts for
50% of cases of hyperprolactinemia. The tumors are clas-
sified as microadenomas (<1 cm in diameter) and macro-
adenomas (less common in women; they may extend as
suprasellar, parasellar, or anterior-inferiorly into the sphe-
noid sinus)11.
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The symptoms may be related directly to the tumor,
such as headache and diplopia, or to the specific hormone
overproduction, e.g., oligo- or amenorrhea, galactorrhea,
mild obesity, hirsutism, frictional dyspareunia, and loss of
libido12. Tumors may also produce growth hormone (30%)
or ACTH (<10%), leading to acromegaly or Cushing’s
disease. MRI is slightly superior to CT in the detection
of microadenomas.
Patients with serum prolactin level above 200 ng/ml
usually have a MRI demonstrable tumor; serum prolac-
tin level above 1000 ng/ml suggests cavernous sinus in-
vasion. About 80% ∑ 90% of microadenomas do not ??.
Insulinoma, i.e. insulin-producing pancreatic islet cell
tumor of the pancreas, has been reported in about 80% of
patients with MEN 1. Insulinomas are the most common
islet cell tumors of the pancreas, with a reported incidence
of 0.8 - 0.9 cases per 1 million population per year. These
tumors occur slightly more often in women than in men,
and the average age at presentation is between 40 and 50
years13. About 40% of these islet cell tumors originate
from β cells, secrete insulin, and are associated with fast-
ing hypoglycemia. In about 60% of cases, the islet cell tu-
mors derive from non-β cell elements. Gastrin is the hor-
mone most commonly secreted by the non-β cell tumors
and is associated with intractable and complicated peptic
ulceration (Zollinger-Ellison syndrome). Both β- and
non-β cell tumors usually are multicentric and small in
origin, and multiple adenomas or diffuse islet cell
hyperplasia commonly occur. In about 30% of patients, the
islet cell tumors are malignant, with local or distant me-
tastases, but these tumors in MEN 1 syndrome often fol-
low a more benign course than sporadic islet cell carcino-
mas. The incidence of malignancy appears to be higher in
non-β cell tumors14,15. The clinical symptoms of insulino-
mas are due to the hypoglycemia induced by excess insu-
lin secretion.
The diagnosis of pancreatic endocrine tumors is usu-
ally made by the recognition of the clinical syndrome
caused by excess hormone production. The most reliable
method of diagnosing an insulinoma is the provocative
test of fasting. Blood glucose and insulin levels are mea-
sured every 4-6 hours during fast. Eighty percent of pati-
ents with insulinoma become symptomatic within 24
hours of starting the fast, and almost all will be symptom-
atic if the fast is continued for 72 hours. The presence of
an elevated insulin level higher than 6 µU/ml along with
concurrent hypoglycemia and an insulin ∑ glucose ratio
greater than 0.3 confirm the diagnosis. Measurement of
the β cell products C-peptide and proinsulin is important
because they both are usually elevated in patients with
insulinoma. Patients who surreptitiously administer insu-
lin to themselves will usually have low levels of C-pep-
tide and proinsulin. Once the diagnosis has been con-
firmed, localization studies are carried out. A majority of
insulinomas are 10-15 mm in diameter and are evenly di-
stributed throughout the pancreas16-18. Dynamic CT
scanning is usually the first localizing study done because
it can detect about two thirds of primary tumors and a ma-
jority of metastatic lesions. When no tumor is seen on CT
scan, visceral angiography with digital subtraction tech-
niques is successful in visualizing lesions in some 60% -
90% of the time. Selective portal venous sampling is reser-
ved mainly for patients whose tumors cannot be visual-
ized with CT or angiography. Portal venous sampling can
define the general area of the tumor in 90% of all patients
and in about 75% of those in whom other localizing tests
have been negative. Histologic diagnosis of these tumors
can be made by CT-guided fine-needle aspiration.
Case Report
In 1996, at age 16, the patient experienced headache,
galactorrhea, primary amenorrhea, and low height for her
age. Laboratory tests showed an increased prolactin level
exceeding 400 ng/ml. CT scan of the pituitary gland re-
vealed a tumor mass, 1.5x0.9 cm in size (1.5 cm anteropo-
steriorly, 0.9 cm craniocaudally). Transnasal selective par-
tial adenomectomy was performed, and postoperative
excisional biopsy showed a prolactinoma (chromophobic
adenoma). Postoperatively, levothyroxine (100 mg) and
hydrocortisone (30 mg) were prescribed as adjuvant the-
rapy because of the postoperatively developed hypopitu-
itarism. Laboratory tests showed decreased glucose lev-
els, which have never been thoroughly explained because
the patient left the hospital. Then, there had been no in-
formation on the patient’s condition for four years, when
she presented again with overt clinical symptoms of hy-
poglycemia, including weakness, tremor, and mental con-
fusion. The patient’s body weight was 158 kg (90 kg in
excess from her previous presentation). Her high body
mass was caused by persistent hypoglycemia, which forced
her to take large amounts of carbohydrates. We knew that
she had a tumor secreting insulin or insulin-like growth
factor (IGF). Laboratory tests pointed to very low glucose
levels. CT and MRI of the abdomen could not be per-
formed because of the patient’s high body weight (158 kg).
An attempt was made to perform i.v. angiography, but the
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needle was too short for her thick fatty tissue mass. Even-
tually, abdominal ultrasonography (US) was tried and, to
Fig. 1a. Abdominal ultrasonogram.
Fig. 1b. Abdominal ultrasonogram.
our surprise, it proved successful revealing a tumor mass
of 26 mm in the distal part of the tail of the pancreas (Figs.
1a and 1b).
Upon consultation with a surgeon, we decided for the
patient to be operated on (Fig. 2). Two days postopera-
tively, a high level of glucose was measured and insulin
therapy had to be introduced. On day 10 postoperatively,
the patient was discharged from the hospital with the fol-
lowing therapy prescribed: hydrocortisone (30 mg),
levothyroxine (100 mg), and insulin (Mixtard 50 penfill,
Novo insulin 16+8 IU). In one year, the patient lost 56 kg
(Figs. 3 and 4).
On the last laboratory testing, the glucose level was
within the normal range, clinical symptoms of diabetes
disappeared, and the patient felt pretty well. On the last
Fig. 2. Tumor extirpation.
Fig. 3. Before the operation.
Fig. 4. One year after the operation.
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hospitalization, glucose levels were within the normal
range and therapy was discontinued. MRI and CT per-
formed one year postoperatively, when the patient had lost
56 kg of her body weight, showed normal abdominal tis-
sue.
The diagnosis of pancreatic insulinoma was verified by
postoperative pathohistology (Fig. 5).
tumors by CT depends on the tumor size and localization.
Although localization of tumors as small as 0.7 cm in di-
ameter has been reported, those of less than 2 cm cannot
be found consistently. The sensitivity of CT for detect-
ing primary insulinomas ranges between 31% and 59%.
On MRI, pancreatic endocrine tumors usually show
low signal intensity on T1-weighted images and high in-
tensity on T2-weighted images. The sensitivity of MRI
is similar to that of CT.
Discussion
Insulinoma is an uncommon but important cause of
hypoglycemia because it is usually curable. It may occur
as an isolated abnormality or as a component of type
MEN 1 syndrome. Diagnosis requires evidence that the
symptoms occur in association with an abnormally low
plasma glucose level, which is generally defined as <50
mg/dl in men, <45 mg/dl in women, and <40 mg/dl in
children. Plasma insulin, proinsulin, C-peptide levels, and
blood lactate with pH should be determined. Patients with
insulin-secreting pancreatic tumor such as insulinoma
usually have increased proinsulin and C-peptide levels
that parallel the levels of insulin. An initial plasma insu-
lin level of >6 µU/ml and certainly that of >10 µU/ml as-
sociated with hypoglycemia is inappropriately high and
strongly suggest an insulin-secreting tumor.
Patients with insulinoma are frequently asymptomatic
when they finally seek medical attention for isolated epi-
sodes of sudden confusion or unconsciousness that have
occurred over a period of years and have become more fre-
quent with time. The episodes characteristically occur in
the postabsorptive period or after an overnight fast, and
are sometimes precipitated by exercise.
Insulinomas are usually too small to be detected by
standard x-ray or CT scan. Once the tumor has been lo-
calized, surgical exploration is performed. Insulinomas are
more difficult to manage, since the lesions are often small
and difficult to find, and multiple lesions commonly ex-
ist. If a single tumor cannot be found, total pancreatec-
tomy may be required for appropriate control of hyper-
insulinism. Distal pancreatectomy is recommended for
small lesions near the pancreatic duct to minimize the risk
of pancreatic fistula. Large lesions of the head of the pan-
creas may require pancreaticoduodenectomy, whereas
those of the body and tail of the pancreas can be treated
with distal pancreatectomy. Insulinomas are identified
about 95% of the time at initial exploration. Blind resec-
Fig. 5. Tumor tissue.
Methods
A plasma insulin concentration of 6 µU/ml (36 pmol/
l) or greater, when plasma glucose is below 45 mg/dl (2.5
mmol/l), indicates an excess of insulin and is consistent
with insulinoma. Plasma glucose falls below 50 mg/dl (2.8
mmol/l) in some normal individuals and may occasion-
ally remain above 50 mg/dl in a patient with insulinoma.
The measurement of C-peptide can be used to distin-
guish endogenous from exogenous hyperinsulinemia. All
insulinoma patients had higher values, and normal indi-
viduals who were hypoglycemic had lower values. In case
of proinsulin, the diagnostic criterion for insulinoma is 5
pmol/l or greater.
Transabdominal US shows pancreatic endocrine tu-
mors as hypoechoic, well circumscribed masses within the
pancreas, whereas liver metastases appear as hyperechoic
lesions. The sensitivity of this technique for detection of
primary tumors is between 19% and 32%, which is con-
siderably below the sensitivity of other imaging tech-
niques. It is therefore of limited value in the assessment
of pancreatic endocrine tumors.
On non-enhanced CT scan, primary pancreatic endo-
crine tumors are poorly visualized. When i.v. contrast is
administered, primary pancreatic endocrine tumors appear
as rounded, enhancing lesions but may be extremely
subtle. The likelihood of detection of pancreatic endocrine
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tion is not recommended when no tumor is identified. A
second exploration using intraoperative US has a greater
than 90% chance of identifying and resecting the le-
sion18,19. If no tumor is identified on second exploration,
then pancreatic biopsy is recommended to rule out β cell
hyperplasia, a condition that can be treated by subtotal
pancreatectomy. Because pancreatic exploration involves
significant risks of inducing pancreatitis and other com-
plications, and because intraoperative identification of a
small insulin secreting tumor requires experience in the
area, patients with a presumptive diagnosis should be re-
ferred to a referral center for evaluation by experienced
physicians prior to surgery. Forty percent of patients with
MEN 1 develop adrenal tumors. Therefore, prior to sur-
gical resection of endocrine tumors, all MEN 1 patients
need to be screened by measuring urinary excretion of
glucocorticoids, mineralocorticoids, catecholamines,
vanillylmandelic acid, metanephrines, and sex hormones.
Two drugs that inhibit insulin secretion are available,
diazoxide and octreotide (a long-acting octapeptic analog
of somatostatin); both drugs also have other effects and
consultation with a physician experienced in their use is
recommended. Resectability is defined by the absence of
metastatic disease and of invasion of the superior mesen-
teric or hepatic arteries. In general, insulinomas carry quite
a good prognosis.
Treatment of pituitary lesions is primarily surgical,
although in some cases pituitary irradiation may suffice.
Patients with prolactin levles of <100 ng/ml and normal
CT or MRI scans, or those who only have microadenomas
can be treated with bromocriptine or be kept under sur-
veillance by an endocrinologist, neurosurgeon and radio-
therapist20. As hyperprolactinemic women are often
hypoestrogenic and appear to be at an increased risk of
developing osteoporosis, treatment with bromocriptine is
preferred. Periodic monitoring of basal prolactin levels and
radiographic evaluation of sella turcica are indicated in
everyone with hyperprolactinemia. Patients should be
evaluated at least quarterly and should undergo repeat CT
or MRI annually for at least additional two years. The
frequency of sellar x-rays can then be reduced if there is
no increase in basal prolactin levels. Individuals with
macroadenomas generally should be treated with bromo-
criptine or surgery only after thorough endocrine testing
of pituitary function and consultation. Bromocriptine, a
dopamine agonist, can be used to treat prolactinomas
medically. Transsphenoidal hypophysectomy is reserved
for patients who fail to respond to bromocriptine and who
have non-prolactin secreting tumors. All patients with
MEN 1 should be followed periodically by measuring
serum prolactin and growth hormone levels.
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Saæetak
VI©ESTRUKA ENDOKRINA NEOPLAZIJA TIPA 1 (MEN 1): PRIKAZ SLU»AJA
M. Vrkljan, M. Doko, B. Vizner, M. Zovak, J. ReπetiÊ, G. RoiÊ, M. Belicza
Hipoglikemija se moæe pojaviti u sklopu sindroma viπestruke endokrine neoplazije tipa 1. Inzulinom je rijedak tumor koji
Ëesto predstavlja dijagnostiËki problem za kliniËara. NeuobiËajeno visoke koncentracije inzulina i C-peptida iz plazme za
vrijeme hipoglikemije potvruju dijagnozu inzulinoma. A. B., 21-godiπnja bolesnica je primljena na kliniku zbog opetovanih
epizoda slabosti, psihiËke konfuznosti i umora s tremorom, πto je ukazivalo na hipoglikemiju. »etiri godine ranije operirala
je prolaktinom hipofize i otada nije imala kontrolnih pregleda. Iste godine javili su se simptomi hipoglikemije, uza znaËajan
porast tjelesne teæine od 90 kg zbog velikih koliËina ugljikohidrata koje joj je obitelj davala zbog Ëestih hipoglikemija. Jedina
dostupna dijagnostiËka tehnika s obzirom na njezinu prekomjernu tjelesnu teæinu od 158 kg, koja bi potvrdila dijagnozu
inzulinoma, bio je ultrazvuk gornjeg abdomena. Ultrazvuk je pokazao tumorsku tvorbu veliËine 26 mm u podruËju repa
guπteraËe. Izvedena je hemipankreatektomija uz splenektomiju. KliniËki znaci hipoglikemije povukli su se nakon operacijskog
zahvata, ali je tada u bolesnice nastupila πeÊerna bolest, pa je uvedeno u terapiju inzulin. Tijekom prve godine nakon operacije
tjelesna se masa pribliæno normalizirala, bolesnica je izgubila 54 kg. Na zadnjoj kontroli su magnetska rezonanca i kompju-
torizirana tomografija pokazale uredan nalaz abdomena.
KljuËne rijeËi: Viπestruka endokrina neoplazija tipa 1, dijagnostika; Viπestruka endokrina neoplazija tipa 1, komplikacije; Hipo-
glikemija, etiologija; Prikaz sluËaja
